Drug-Induced Nutrient Deficiencies

Pediatric Clinics of North America

Volumn 56, Issue 5, 2009, Pages 1211-1224

  Felípez, Lina ^a   Sentongo, Timothy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adverse drug reactions; Adverse effects; Drug interactions; Drug therapy; Iatrogenic disease; Nutrient deficiency; Pharmacogenomics

Indexed keywords

ALPHA TOCOPHEROL; ASCORBATE OXIDASE; BETA CAROTENE; CARBAMAZEPINE; COLESTYRAMINE; DIURETIC AGENT; FOSCARNET; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; ISONIAZID; LOOP DIURETIC AGENT; METHOTREXATE; MIGLITOL; MINERAL OIL; NEOMYCIN; PENTAMIDINE; PHENOBARBITAL; PHENYTOIN; PROTON PUMP INHIBITOR; PYRIMETHAMINE; RETINOL; SALAZOSULFAPYRIDINE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG; VALPROIC ACID; VITAMIN D; VITAMIN K GROUP; ZINC;

BACTERIAL INFECTION; CALCIUM EXCRETION; CHILD NUTRITION; CLINICAL FEATURE; CONSTIPATION; DIABETES MELLITUS; DIAGNOSTIC TEST; DIARRHEA; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; MAGNESIUM DEFICIENCY; MALABSORPTION; NEPHROTOXICITY; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OBESITY; PATIENT MONITORING; PHARMACOGENOMICS; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STEATORRHEA; ZINC URINE LEVEL;

AVITAMINOSIS; CHILD; DRUG INTERACTIONS; DRUG THERAPY; DRUG TOXICITY; HUMANS; IATROGENIC DISEASE; MALNUTRITION; TRACE ELEMENTS;

EID: 72049117099     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.06.004     Document Type: Review

References (78)

1. Availabe at:. www.jointcommission.org/sentinelevents/se_glossary.htm Accessed May 20, 2009
2. Woods D., Thomas E., Holl J., et al. Adverse events and preventable adverse events in children. Pediatrics 115 1 (2005) 155-160
3. Leape L.L., Bates D.W., Cullen D.J., et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 274 1 (1995) 35-43
4. Holdsworth M.T., Fichtl R.E., Behta M., et al. Incidence and impact of adverse drug events in pediatric inpatients. Arch Pediatr Adolesc Med 157 1 (2003) 60-65
5. Nies A., and Spielberg S. Goodman & Gilman's: the pharmacological basis of therapeutics. In: Hardman J., Limbird L., Molinoff P., Ruddon R., and Gilman A.G. (Eds). Principles of therapeutics. 9th edition (1996), McGraw-Hill, New York 43-62
6. Evans W.E. Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. Pharmacogenetics 12 3 (2002) 181-182
7. Cohen L.K., George W., and Smith R. Isoniazid-induced acne and pellagra. Occurrence in slow inactivators of isoniazid. Arch Dermatol 109 3 (1974) 377-381
8. Muratake T., Watanabe H., and Hayashi S. Isoniazid-induced pellagra and the N-acetyltransferase gene genotype. Am J Psychiatry 156 4 (1999) 660
9. McLeod H.L., and Evans W.E. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41 (2001) 101-121
10. Tonstad S., Refsum H., Ose L., et al. The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. J Pediatr 132 2 (1998) 365-368
11. McCabe B.J. Prevention of food-drug interactions with special emphasis on older adults. Curr Opin Clin Nutr Metab Care 7 1 (2004) 21-26
12. Hanninen S.A., Darling P.B., Sole M.J., et al. The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol 47 2 (2006) 354-361
13. McKenzie S.A., Macnab A.J., and Katz G. Neonatal pyridoxine responsive convulsions due to isoniazid therapy. Arch Dis Child 51 7 (1976) 567-568
14. Lukert B.P., and Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. [see comment]. Ann Intern Med 112 5 (1990) 352-364
15. Kessler D.A. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 269 21 (1993) 2765-2768
16. Nations S.P., Boyer P.J., Love L.A., et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. [see comment]. Neurology 71 9 (2008) 639-643
17. Safer D.J., Allen R.P., and Barr E. Growth rebound after termination of stimulant drugs. J Pediatr 86 1 (1975) 113-116
18. Sund A.M., and Zeiner P. Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children?. Nord J Psychiatry 56 1 (2002) 53-57
19. Charach A., Figueroa M., Chen S., et al. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 45 4 (2006) 415-421
20. Dunican K.C., Desilets A.R., and Montalbano J.K. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother 41 9 (2007) 1445-1455
21. Martin A.E., and Montgomery P.A. Acarbose: an alpha-glucosidase inhibitor. Am J Health Syst Pharm 53 19 (1996) 2277-2290 [quiz: 2336-7]
22. Sels J.P., Huijberts M.S., and Wolffenbuttel B.H. Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother 1 1 (1999) 149-156
23. Van de Laar F.A., Lucassen P.L., Akkermans R.P., et al. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 4 (2006) CD005061
24. Hauptman J.B., Jeunet F.S., and Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 55 Suppl 1 (1992) 309S-313S
25. Clark J.H., Russell G.J., Fitzgerald J.F., et al. Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation. Am J Dis Child 141 11 (1987) 1210-1212
26. Knodel L.C., and Talbert R.L. Adverse effects of hypolipidaemic drugs. Med Toxicol Adverse Drug Exp 2 (1987) 10-32
27. Bays H.E., and Dujovne C.A. Drug interactions of lipid-altering drugs. Drug Saf 19 5 (1998) 355-371
28. Sheth R.D. Metabolic concerns associated with antiepileptic medications. Neurology 63 10 Suppl 4 (2004) S24-S29
29. Mintzer S., Boppana P., Toguri J., et al. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47 3 (2006) 510-515
30. Gissel T., Poulsen C.S., and Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf 6 3 (2007) 267-278
31. Horwitt M.K., Harvey C.C., Dahm Jr. C.H., et al. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann N Y Acad Sci 203 (1972) 223-236
32. Thurnham D.I., Davies J.A., Crump B.J., et al. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 23 Pt 5 (1986) 514-520
33. Bhat R.V., and Deshmukh C.T. A study of vitamin K status in children on prolonged antibiotic therapy. Indian Pediatr 40 1 (2003) 36-40
34. Alperin J.B. Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. JAMA 258 14 (1987) 1916-1919
35. Kelly S.M., Shorthouse M., Cotterell J.C., et al. A 3-month, double-blind, controlled trial of feeding with sucrose polyester in human volunteers. Br J Nutr 80 1 (1998) 41-49
36. Neuhouser M.L., Rock C.L., Kristal A.R., et al. Olestra is associated with slight reductions in serum carotenoids but does not markedly influence serum fat-soluble vitamin concentrations. Am J Clin Nutr 83 3 (2006) 624-631
37. Thomson A.B., Hunt R.H., and Zorich N.L. Review article: olestra and its gastrointestinal safety. Aliment Pharmacol Ther 12 12 (1998) 1185-1200
38. Barlam T.F., and McCloud E. Severe gastrointestinal illness associated with olestra ingestion. J Pediatr Gastroenterol Nutr 37 1 (2003) 95-96
39. Zenuk C., Healey T., Donnelly J., et al. Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy. Can J Clin Pharmacol 10 4 (2003) 184-188
40. Bailey A.L., Finglas P.M., Wright A.J., et al. Thiamin intake, erythrocyte transketolase (EC 2.2.1.1) activity and total erythrocyte thiamin in adolescents. Br J Nutr 72 1 (1994) 111-125
41. Finglas P.M. Thiamin. Int J Vitam Nutr Res 63 4 (1993) 270-274
42. Rocha R.M., Silva G.V., de Albuguergue D.C., et al. Influence of spironolactone therapy on thiamine blood levels in patients with heart failure. Arquivos Brasileiros de Cardiologia 90 5 (2008) 324-328
43. Ruscin J.M., Page II R.L., and Valuck R.J. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36 5 (2002) 812-816
44. Snow C.F. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. [see comment]. Arch Intern Med 159 12 (1999) 1289-1298
45. Lambie D.G., and Johnson R.H. Drugs and folate metabolism. Drugs 30 2 (1985) 145-155
46. Young R.C., and Blass J.P. Iatrogenic nutritional deficiencies. Annu Rev Nutr 2 (1982) 201-227
47. Halsted C.H. The intestinal absorption of folates. Am J Clin Nutr 32 4 (1979) 846-855
48. West R.J., and Lloyd J.K. The effect of cholestyramine on intestinal absorption. Gut 16 2 (1975) 93-98
49. Tonstad S., Sivertsen M., Aksnes L., et al. Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch Dis Child 74 2 (1996) 157-160
50. Meyrick Thomas R.H., Rowland Payne C.M., et al. Isoniazid-induced pellagra. Br Med J (Clin Res Ed) 283 6286 (1981) 287-288
51. Darvay A., Basarab T., McGregor J.M., et al. Isoniazid induced pellagra despite pyridoxine supplementation. Clin Exp Dermatol 24 3 (1999) 167-169
52. Pellock J.M., Howell J., Kendig Jr. E.L., et al. Pyridoxine deficiency in children treated with isoniazid. Chest 87 5 (1985) 658-661
53. Steichen O., Martinez-Almoyna L., and De Broucker T. [Isoniazid induced neuropathy: consider prevention]. Rev Mal Respir 23 2 Pt 1 (2006) 157-160
54. Alao A.O., and Yolles J.C. Isoniazid-induced psychosis. Ann Pharmacother 32 9 (1998) 889-891
55. Snider Jr. D.E. Pyridoxine supplementation during isoniazid therapy. Tubercle 61 4 (1980) 191-196
56. De Vivo D.C., Bohan T.P., Coulter D.L., et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 39 11 (1998) 1216-1225
57. Raskind J.Y., and El-Chaar G.M. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34 5 (2000) 630-638
58. Van Wouwe J.P. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 65 3 (1995) 211-214
59. Lheureux P.E.R., and Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clinical Toxicol(Phila) 47 2 (2009) 101-111
60. Liamis G., Milionis H., and Elisaf M. A review of drug-induced hyponatremia. [see comment]. Am J Kidney Dis 52 1 (2008) 144-153
61. Gennari F.J. Hypokalemia. [see comment]. N Engl J Med 339 7 (1998) 451-458
62. al-Ghamdi S.M., Cameron E.C., and Sutton R.A. Magnesium deficiency: pathophysiologic and clinical overview. [see comment]. Am J Kidney Dis 24 5 (1994) 737-752
63. Navaneethan S.D., Sankarasubbaiyan S., Gross M.D., et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 38 5 (2006) 1320-1322
64. Arnaud M.J. Update on the assessment of magnesium status. Br J Nutr 99 Suppl 3 (2008) S24-S36
65. Jayaweera D.T. Minimising the dosage-limiting toxicities of foscarnet induction therapy. Drug Saf 16 4 (1997) 258-266
66. Abrams S.A., and O'Brien K.O. Calcium and bone mineral metabolism in children with chronic illnesses. Annu Rev Nutr 24 (2004) 13-32
67. Lee C.T., Chen H.C., Lai L.W., et al. Effects of furosemide on renal calcium handling. Am J Physiol Renal Physiol 293 4 (2007) F1231-F1237
68. Stier Jr. C.T., and Itskovitz H.D. Renal calcium metabolism and diuretics. Annu Rev Pharmacol Toxicol 26 (1986) 101-116
69. Jacobson M.A., Gambertoglio J.G., Aweeka F.T., et al. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 72 5 (1991) 1130-1135
70. Gearhart M.O., and Sorg T.B. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. Ann Pharmacother 27 3 (1993) 285-289
71. Broun E.R., Greist A., Tricot G., et al. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA 264 11 (1990) 1441-1443
72. Fiske D.N., McCoy III H.E., and Kitchens C.S. Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol 46 2 (1994) 147-150
73. Cai L., Li X.K., Song Y., et al. Essentiality, toxicology and chelation therapy of zinc and copper. Curr Med Chem 12 23 (2005) 2753-2763
74. Fosmire G.J. Zinc toxicity. Am J Clin Nutr 51 2 (1990) 225-227
75. Willis M.S., Monaghan S.A., Miller M.L., et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 123 1 (2005) 125-131
76. Reyes A.J., Olhaberry J.V., Leary W.P., et al. Urinary zinc excretion, diuretics, zinc deficiency and some side-effects of diuretics. S Afr Med J 64 24 (1983) 936-941
77. Khedun S.M., Naicker T., and Maharaj B. Zinc, hydrochlorothiazide and sexual dysfunction. Cent Afr J Med 41 10 (1995) 312-315
78. Yoshida Y., Higashi T., Nouso K., et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 55 6 (2001) 349-355